Drug safety without borders: Concerns about bupropion [1]

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 5, 2002, Pages 447-

  Mintzes, Barbara ^a   Bassett, Ken ^a   Wright, James M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

CANADA; DEPRESSION; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE SYSTEM; HUMAN; INDUSTRIALIZATION; LETTER; LICENSING; POSTMARKETING SURVEILLANCE; PRESCRIPTION; SEIZURE; SMOKING CESSATION; UNITED KINGDOM;

EID: 0036375008     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Bupropion (Zyban, Wellbutrin SR): Reports of deaths, seizures, serum sickness
2. Prescription-event monitoring: Recent progress and future horizons
3. Under-reporting of adverse drug reactions in general practice
4. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
5. Drugs and adverse drug reactions. How worried should we be?
6. Postmarketing drug surveillance: What it would take to make it work
7. Cisapride, before and after: Still waiting for ADE-reporting reform